Targeting Notch/Delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF) pathways by an anti-DLL4/Anti-VEGF bi-specific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency in

Source URL: posters.omed.s3.amazonaws.com

Preclinical and Clinical Activity of Anti-DLL4 (Demcizumab) in Combination with Gemcitabine Plus nab-Paclitaxel in Pancreatic Cancer Manuel Hidalgo*, Antonio Cubillo*, Robert Stagg**, Jakob Dupont**, Wan-Ching Yen**, Tim

Source URL: s3.amazonaws.com

Dual targeting of delta-like ligand 4 (DLL4) and programmed death 1 (PD1) inhibits tumor growth and generates enhanced long-term immunological memory. Minu K. Srivastava, Christopher L. Murriel, Julie Roda, Hyun-Bae Jie,

Source URL: posters.omed.s3.amazonaws.com

A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM, anti-DLL4) and Gemcitabine (GEM) with or without Nab-Paclitaxel in Patients with Pancreatic Cancer Dose Level – mg/kg Median age (years)

Source URL: posters.omed.s3.amazonaws.com

A First-in-Man Phase 1a Study of the Bispecific Anti-DLL4/Anti-VEGF Antibody OMP-305B83 in Patients with Previously Treated Solid Tumors Jimeno A1, Moore K2, Gordon M3, Chugh R4, Diamond J1, Aljumaily R2, Stagg R5, Dupon

Source URL: publications.oncomed.com

A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM, anti-DLL4) and Gemcitabine (GEM) with or without Nab-Paclitaxel in Patients with Pancreatic Cancer 1Hidalgo Patient Demographics (n=47) DEM + GEM

Source URL: s3.amazonaws.com

Dual targeting of the DLL4 and VEGF pathways with a bi-specific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency Wan-Ching Yen, Marcus M. Fischer, Gretchen Argast, Breanna Wallace, Min Wan

Source URL: posters.omed.s3.amazonaws.com

Co-Targeting of Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF) with Programmed Death 1 (PD1) blockade inhibits tumor growth and facilitates anti-tumor immune responses. Minu K. Srivastava, Chr

Source URL: posters.omed.s3.amazonaws.com

Effects of anti-DLL4 treatment on non-small cell lung cancer (NSCLC) human xenograft tumors Alayne Brunner, Fiore Cattaruzza, Wan-Ching Yen, Pete Yeung, Marcus Fischer, Belinda Cancilla, Christopher L. Murriel, Gilbert O

Source URL: posters.omed.s3.amazonaws.com

Supplementary figure 1 Schematic representation of DLL4 locus in Homo sapiens chromosome 15, GRCh38 Primary Assembly. DLL4 mRNA starting fromis shown in red boxes; DLL4-AS starting fromand ending at 4

Source URL: vascularcell.com

• DLL4
• RNA
• Homo sapiens